Vivos Therapeutics, Inc. ((VVOS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vivos Therapeutics’ latest earnings call painted a cautiously optimistic picture, mixing clear operational progress with equally clear financial strain. Management highlighted solid revenue growth and strong patient demand from its new medical-provider model, yet investors were reminded that the pivot carries heavy costs, persistent cash burn, and looming debt obligations.
Revenue Growth and Stable Gross Margins
Full-year 2025 revenue climbed 16% to $17 million, adding $2.4 million versus 2024 as the strategic pivot began to show up in the numbers. Gross profit rose 17% to $10.5 million while gross margin held at 60%, signaling that the new revenue mix is not diluting profitability at the gross level.
SCN Diagnostics and Treatment as Core Growth Engine
The Sleep Center of Nevada franchise emerged as the primary growth driver, with sleep testing revenue reaching about $6 million in 2025, up roughly $4.8 million from the prior year. Treatment revenue from SCN contributed another $2.2 million, underscoring that the integrated diagnostic-and-therapy model is central to Vivos’ long-term strategy.
In-Network Access and Overwhelming Patient Demand
SCN’s new in-network status with multiple commercial insurers and Medicare is dramatically expanding access, with two onboarded locations fully booked through April 2026. Management said they are processing fewer than 40% of interested patients, pointing to substantial unmet demand that could translate into future revenue if capacity issues are solved.
Affiliation Model and High-Potential SO Team Economics
Vivos is building out an MSO/DSO-style affiliation model around Sleep Optimization teams, with about 1.5 teams now operating across two SCN sites and more expected in 2026. Each SO team is projected to generate collections well above $500,000 per month with contribution margins above 50%, supported by Nevada revenue per case just under $5,000 and relatively modest sub-$1 million upfront capital per affiliation.
Capital Raises Shore Up, but Don’t Solve, Liquidity
Post-year-end financings provided an important but limited liquidity bridge, with $4.6 million raised through a warrant transaction in January 2026 and another $2.25 million from a private placement in April. These moves strengthened stockholders’ equity and extended runway, but do not fully offset a lean year-end cash position or ongoing operating cash burn.
Operational and Clinical Momentum Supports the Pivot
Management described increasing support from medical sleep specialists and expanding capacity at SCN to meet heavy patient interest. Ongoing R&D work, anticipated case studies, and inbound inquiries from large specialty groups suggest rising clinical validation and the potential for additional affiliations that could scale the medical-provider model.
Escalating Operating Expenses and Deepening Net Loss
The pivot remains expensive, with operating expenses jumping to $30.4 million from $20.2 million, driven mainly by a $9.8 million increase in general and administrative costs. Net loss widened to $21.2 million for 2025, reflecting both the cost of building out SCN and roughly $3 million in identified one-time professional and other integration-related expenses.
Cash Burn and Thin Year-End Cash Cushion
Net cash used in operating activities increased to about $15.3 million from $12.7 million as the company invested heavily in its new model. Cash and equivalents were only about $2 million at year-end 2025, leaving Vivos reliant on fresh capital and tighter execution to navigate the next phase of its transformation.
Higher Leverage and Upcoming Debt Maturities
Total liabilities surged to roughly $26.7 million from $7.3 million, largely tied to financing the SCN acquisition and build-out. About $8.3 million of that has been reclassified as current debt due in 2026, putting refinancing or repayment firmly on the near-term agenda and adding balance sheet risk to the story.
Pressure on Legacy Product Revenue and Pricing
The legacy oral appliance and tooth positioner business weakened, generating around $6.5 million in 2025, an 18% decline from $7.9 million despite higher unit volume. Increased discounting of about $1.6 million versus roughly $200,000 last year and a shift toward lower-priced tooth positioners weighed on average selling prices and compressed this once-core revenue stream.
Quarterly Volatility from Provider Shortages
Revenue volatility remains an operational risk, with Q4 2025 sales dropping to approximately $3.8 million from $6.8 million in Q3 as provider absences and attrition cut available doctor days. Management expects new hires and onboarding to restore much of that lost productivity by the second quarter of 2026, but the episode highlights how dependent results are on staffing.
Rising Cost of Sales and Depreciation Burden
Cost of sales increased by around $900,000 to $6.9 million, driven by roughly $1.1 million in higher diagnostic costs and an additional $0.5 million in SCN-related staffing. Depreciation and amortization more than doubled to about $1.3 million, reflecting investments and acquired assets that support the SCN and affiliation infrastructure.
Guidance and Path Toward Profitability
Management guided to stronger 2026 revenue and margins as the medical-provider model scales, aiming for SO teams to ramp within about 60 days and reach full collections in six-plus months. They reiterated an ambition to achieve cash-flow break-even by year-end 2026 and suggested that roughly doubling the current $17 million revenue run-rate by 2027 would be needed to move the company into net-income-positive territory.
Vivos Therapeutics’ earnings call outlined a high-upside but high-risk transition, with SCN-driven growth, attractive SO team economics, and strong demand offset by steep losses, leverage, and a tight cash position. For investors, the story now hinges on whether the company can fund and execute its ramp quickly enough to turn today’s promising operating metrics into sustainable profitability.